Drug Discovery

ExpressionEdits secures $13m to develop protein-based therapies

UK-based biotechnology company ExpressionEdits has secured $13m in a seed funding round to advance the development of protein based therapies leveraging artificial intelligence (AI)-driven intronization technology.

Lucy Therapeutics secures $12.5m for neurological treatment development

Lucy Therapeutics (LucyTx) has secured $12.5m in additional financing round to advance the development of new treatments for Alzheimer's and Parkinson's diseases.

RevolKa signs deal with Daiichi Sankyo for functional proteins

Venture-backed biotechnology company RevolKa has entered into a master service agreement with Daiichi Sankyo for functional proteins.

Radar Therapeutics secures $13.4m to develop programmable medicines

Radar Therapeutics has successfully completed an oversubscribed seed funding round, raising $13.4m for developing smart programmable medicines.

Teva and Alvotech launch SIMLANDI in US for arthritis

Teva and Alvotech have announced the US launch of SIMLANDI (adalimumab-ryvk) injection, as an interchangeable biosimilar to the reference product Humira to treat arthritis.

ERS Genomics and IRBM sign deal for CRISPR technology

ERS Genomics and IRBM have entered into a non-exclusive license agreement, granting the latter access to ERS Genomics' extensive clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 patent portfolio.

FogPharma and ARTBIO collaborate to co-develop new cancer therapies

FogPharma has partnered with ARTBIO to co-develop Helicon-enabled alpha radioligand therapies (HEARTs), a new class of treatments aimed at improving outcomes for cancer patients.

PharmaLogic launches new radiopharmaceutical facility in New York, US

PharmaLogic, a contract development and manufacturing organization (CDMO) and provider of radiopharmacy solutions, has announced the launch of its new radiopharmaceutical manufacturing and research facility at the Bronx in New York city, US.

Aardvark Therapeutics secures $85m in Series C funding round

Aardvark Therapeutics has secured $85m in an oversubscribed Series C financing round, with Decheng Capital spearheading the investment, to complete studies of ARD-101.